关注2型糖尿病合并非酒精性脂肪性肝病的肝脏结局

doi:10.3969/j.issn.1672-5069.2017.03.004

Abstract

Yu Hongyan, Di Fusheng. Endocrinologists should pay attention to the outcome of liver diseases in patients with diabetes and non-alcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 267-270.

References

[1] Vernon G,Baranova A,Younossi ZM.Systematic review:the epidemiolory and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther,2011,34:274-285.
[2] Fan JG,Li F,Cai XB,et al.Effects of nonalcoholic fatty liver disease on the development of metabolic disorders.J Gastroenterol Hepatol,2007,22:1086-1091.
[3] 贾国瑜,李雪粉,邸阜生,等. 2型糖尿病患者社会经济地位与非酒精性脂肪肝相关性的回顾性队列研究.中华肝脏病杂志, 2015,10(23):760-764.
[4] 张林彬,苄华,颜红梅,等. 2型糖尿病患者肝脏脂肪含量与肝病结局的相关性研究. 中华内分泌代谢杂志,2014,30:3-7.
[5] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南. 实用肝脏病杂志,2007,10(1):1-3.
[6] European Association for the Study of the Liver(EASL),European Association for the Study of Diabetes(EASD),European Association for the Study of Obesit (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol,2016,64(6):1388-1402.
[7] Adams LA,Sanderson S,Lindor KD,et al.The histological course of nonalcoholic fatty liver disease:a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol,2005,42(1):132-138.
[8] Sun C,Fan JG,Qiao L.Potential epigenetic mechanism in non-alcoholic fatty liver disease. Int J Mol Sci,2015,16(3):5161-5179.
[9] Leite NC,Villela-Nogueira CA,Pannain VL,et al.Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes:prevalences and correlated factors. Liver Int,2011,31:700-706.
[10] Bhaha N,Jouness RI,Bugianesi E.Epidemiology and natural history of patients with NAFLD. Curr Pharm Des,2013,19:5169-5176.
[11] Jou J,Choi SS,Diehl AM,et al.Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis,2008,28:370-379.
[12] Anstee QM,Day CP.The genetics of NAFLD. Nat Rev Gastroenterol Hepatol,2013,10(11):645-655.
[13] Baffy G.MicroRNAs in nonalcoholic fatty liver disease. Clin Med,2015,4(12):1977-1988.
[14] Pirola CJ,Gianotti TF,Burgueno AL,et al.Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut,2013,62(9):1356-1363.
[14] Xia MF,Yan HM.Standardized ultrasound hepatic /renal ratio and hepatic attenuation rate to quantify liver fat content:An improvement method. Obesity,2012,20(2):444-452.
[15] 邵金双,邸阜生.影像检查对脂肪性肝病的诊断评价.实用糖尿病杂志,2015,1(11):10-12.
[16] Feldstein AE,Wieckowska A,Lopez AR,et al.Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis:a multicenter validation study. Hepatology,2009,50(4):1072-1078.
[17] Hyysalo J,M nnist VT,Zhou Y,et al. A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol,2014,60:839-846.
[18] Angulo P,Hui JM,Marchesini G,et al.The NAFLD fibrosis score:a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology,2007,45(4):846-854.
[19] Halfon P,Munteanu M,Poynard T.FibroTest as a non-invasive marker of Iiver fibrosis.Gastroenterol Clin Biol,2008,32(6 SuppI 1):22-39.
[20] Yoshimura E,Kumahara H,Tobina T,et al.Lifestyle intervention involving calorie restriction with or without aerobic exercise training improves liver fat in adults with visceral adiposity. J Obes,2014,2014:197-216.
[21] Ratziu V,Bellentani S, Cortez-Pinto H,et al.A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol,2010,53(2):372-384.
[22] Vilar-Gomez E,Martinez-Perez Y,Calzadilla-Bertot L,et al.Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology,2015,149:367-378.
[23] Musso G,Gambino R,Cassader M,et al.A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology,2010,52(1):79-104.
[24] Wang XC,Gusdon AM,Liu H,et al.Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. World J Gastroenterol,2014,20(40):14821-14830.
[25] Kim SG,Kim BK,Kim K,et al.Bile acid nuclear receptor farnesoid X receptor:Therapeutic target for nonalcoholic fatty liver disease. Endocrinol Metab(Seoul),2016,31(4):500-504.

Endocrinologists should pay attention to the outcome of liver diseases in patients with diabetes and non-alcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[5]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[6]	Zhu Yage, Liu Jinfeng.. Therapeutic efficacy of adenosine methionine and glycyrrhizin combination in treatment of patients with alcoholic cirrhosis and its effect on serum BGP levels [J]. Journal of Practical Hepatology, 2019, 22(6): 872-875.
[7]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[8]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[9]	Liu Li, Yang Lie, Chen Haiyang, et al.. Changes of hemodynamics after splenectomy combined with pericardial devascularization in patients with cirrhotic portal hypertention complicated by splenic artery steal syndrome [J]. Journal of Practical Hepatology, 2019, 22(6): 884-887.
[10]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[11]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[12]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[13]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[14]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[15]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.